Arrotex Biologics

Arrotex Biologics is the specialized biologics and biosimilars division of Arrotex Pharmaceuticals, Australia's largest generic pharmaceutical company. The company focuses on the commercialization and distribution of high-quality biosimilar medicines across various therapeutic areas, including oncology, immunology, and endocrinology. By partnering with global biotechnology leaders like Alvotech and Samsung Bioepis, Arrotex Biologics aims to improve patient access to affordable biologic therapies within the Australian healthcare system. Their portfolio includes biosimilar versions of major reference products such as adalimumab, rituximab, and bevacizumab. The division plays a critical role in supporting the sustainability of the Pharmaceutical Benefits Scheme (PBS) by providing cost-effective alternatives to expensive originator biologics. Arrotex Biologics leverages its parent company's extensive pharmacy and hospital distribution network to ensure nationwide availability of its products.